Patient-derived glioblastoma cells were pre-treated with 1 (100 nM) or vehicle (0.01% DMSO) for 24 h, followed by TNFα (50 μg/mL, 15 min) or vehicle (0.1% BSA/PBS, 15 min). The gene discussed is TNF; the disease is glioblastoma.